The first-ever National Dialogue for Access to Psychedelics in Canada takes place on Monday, April 20th, convening leaders from across the country.

The full-day event will bring together stakeholders from across the country to advance a national conversation on expanding safe, legal and equitable access to psychedelics in Canada. Participants will contribute perspectives from clinical practice, academic research, lived experience, healthcare delivery, and industry innovation.

“We are thrilled to bring stakeholders together for this historic meeting, where we can come together for a common cause and work towards a unified voice for moving things forward in a good way for all Canadians.” Rielle Capler, MHA, PhD , Executive Director of MAPS Canada. 

“What’s unique about this event is that it’s a dialogue, rather than a conference. This is the time for intentional coordination. It’s very exciting, and we are hoping that these results in a consensus call to action,” said Reverdi Darda, CEO of ATMA CENA, a network of psychedelic treatment centres, and Board Chair at MAPS Canada.

“The National Dialogue on Psychedelic Access in Canada represents a milestone in the evolution of the sector and a renewed call on government for legal access to safe, effective and affordable treatment options for a range of important issues,” said Austin Miller, President of Bluestem API Inc., a psychedelic medicines company, and Board Chair of PsyCan, Canada’s Psychedelic Industry Association.